{
  "id": "human-leukocyte-antigen",
  "title": "Human Leukocyte Antigen",
  "lang": "en",
  "source_lang": "en",
  "summary": "Human leukocyte antigens are highly variable cell-surface proteins that present peptides to immune cells and strongly influence transplantation compatibility and disease susceptibility.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "HLA",
    "human leucocyte antigen",
    "human leukocyte antigen system",
    "human major histocompatibility complex"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/human-leukocyte-antigen/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/human-leukocyte-antigen/",
      "json": "https://aiwiki.page/zh/human-leukocyte-antigen.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Human leukocyte antigen (HLA) is the name given to the human major histocompatibility complex and, more specifically, to the cell-surface molecules encoded by its principal antigen-presenting genes. These molecules display fragments of proteins to the immune system, allowing immune cells to monitor intracellular activity and material taken up from the extracellular environment. Although their name reflects their discovery on white blood cells, HLA molecules are not restricted to these cells: class I molecules occur on nearly all nucleated cells, while class II molecules are concentrated on specialized antigen-presenting cells.\n\nThe HLA system connects molecular recognition with several major biological and clinical processes. It helps determine which microbial or tumor-derived peptides can be recognized by T cells, contributes to immune tolerance, and constitutes a major barrier to transplantation between genetically different individuals. Particular HLA variants also influence susceptibility to some autoimmune diseases, infectious diseases, and drug hypersensitivity reactions. These effects arise from differences in peptide presentation, immune-cell interactions, and gene regulation rather than from a simple distinction between “strong” and “weak” immunity.\n\nThe HLA region lies on chromosome 6 and is among the most genetically variable regions of the human genome. Its complexity encompasses classical peptide-presenting molecules, nonclassical molecules with specialized functions, and neighboring genes involved in inflammation and antigen processing. Understanding HLA therefore requires attention to molecular structure, inheritance, population diversity, laboratory nomenclature, and the distinct ways in which HLA differences affect immunity."
    },
    {
      "heading": "Discovery and establishment of the HLA system",
      "text": "The HLA system emerged from research on blood-cell antigens and the rejection of transplanted tissues. Early transplantation experiments showed that graft survival depended strongly on genetic relationships between donor and recipient. Work in mice, notably by Peter Gorer and George Snell, established the importance of the H-2 histocompatibility system. These findings provided a framework for investigating comparable inherited differences in humans, although human populations could not be studied through the controlled breeding experiments used in laboratory animals.\n\nIn 1958, Jean Dausset described a leukocyte antigen detected by an antibody in serum from a person who had received multiple blood transfusions. This specificity, initially called MAC, was subsequently associated with HLA-A2. Related investigations by Jon van Rood, Rose Payne, and other researchers used sera from previously pregnant women and transfused individuals. Such sera sometimes contained antibodies against leukocytes from other people because pregnancy or transfusion had exposed the immune system to nonself antigens. Patterns of antibody binding revealed that these antigens formed an inherited system rather than a collection of unrelated blood-cell markers.\n\nInternational Histocompatibility Workshops, beginning in 1964, were central to organizing the field. Laboratories exchanged sera and cell panels, compared results, and developed shared definitions of antigen specificities. Family studies demonstrated that several HLA determinants were usually inherited together. This established the concept of linked HLA loci and made it possible to distinguish the major antigen series that became HLA-A, HLA-B, and later HLA-C. Investigations of mixed lymphocyte reactions and related cellular assays helped identify the class II region.\n\nA second conceptual advance established what histocompatibility molecules actually do. In 1974, Rolf Zinkernagel and Peter Doherty showed, in a mouse viral-infection model, that cytotoxic T-cell recognition depended on both the viral antigen and the host histocompatibility type. This phenomenon, called MHC restriction, explained why foreign material alone was insufficient for many T-cell responses. Subsequent work identified short peptides as the material displayed by MHC molecules.\n\nStructural studies then connected genetics with function. In 1987, X-ray crystallography of HLA-A2 by Pamela Bjorkman and colleagues revealed a groove capable of binding peptides. Later class II structures demonstrated a related but distinct architecture. Dausset, Snell, and Baruj Benacerraf received the 1980 Nobel Prize in Physiology or Medicine for discoveries concerning genetically determined structures regulating immunological reactions; Zinkernagel and Doherty received the same prize in 1996 for their work on cell-mediated immune recognition."
    },
    {
      "heading": "Genomic organization and inheritance",
      "text": "The HLA region occupies approximately 3.6 million base pairs on the short arm of chromosome 6, at 6p21.3. Exact boundaries vary with whether the discussion concerns the classical MHC or the broader extended MHC. The region contains many genes in addition to those encoding classical HLA molecules, including genes involved in antigen processing, inflammatory signaling, and the complement system. Its unusually dense organization and extensive genetic variation make associations within this region difficult to interpret without detailed mapping.\n\nThe classical class I genes are HLA-A, HLA-B, and HLA-C. Each encodes a membrane-associated heavy chain that combines with beta-2-microglobulin, whose gene lies on chromosome 15 rather than in the HLA region. The principal classical class II molecules are HLA-DP, HLA-DQ, and HLA-DR. DP and DQ consist of alpha and beta chains encoded by paired loci, principally DPA1/DPB1 and DQA1/DQB1. DR contains an alpha chain encoded by DRA and a beta chain encoded by DRB1; depending on the inherited haplotype, an additional expressed beta-chain gene, DRB3, DRB4, or DRB5, may also be present.\n\nThe interval conventionally called the class III region contains genes such as those encoding complement components C2, C4, and factor B, as well as inflammatory mediators including tumor necrosis factor. “Class III” is a positional and historical designation, not a third family of peptide-presenting HLA molecules. Other genes in or near the region encode nonclassical class I molecules, peptide-loading machinery, and stress-associated ligands.\n\nHLA genes are expressed codominantly: an individual ordinarily expresses inherited variants from both parents. A particular version of a gene is an allele, while the linked set of variants carried on one chromosome is a haplotype. Because nearby HLA loci are usually transmitted together, family members can share an extended set of HLA variants. Under the standard model in which each parent has two distinguishable haplotypes, full siblings have a one-in-four probability of inheriting the same two parental haplotypes, a one-in-two probability of sharing one, and a one-in-four probability of sharing neither.\n\nThese probabilities describe inheritance rather than a guarantee of complete molecular identity. Recombination can occur within the region, and some families have repeated or otherwise indistinguishable haplotypes. Strong linkage disequilibrium—the nonrandom association of variants at different loci—also means that a disease-associated HLA marker may identify a broader inherited segment rather than the causal variant itself."
    },
    {
      "heading": "Molecular architecture and peptide binding",
      "text": "Class I and class II HLA molecules are membrane glycoproteins with a peptide-binding platform above immunoglobulin-like supporting domains. Their related architecture enables them to perform the same general task—displaying peptides—while differing in the sources, lengths, and binding arrangements of those peptides. Most clinically important HLA polymorphisms cluster in or near the peptide-binding region, where changes in amino acid sequence can alter the repertoire of peptides displayed to immune cells.\n\nA classical class I molecule contains a heavy chain with three extracellular domains, designated alpha-1, alpha-2, and alpha-3, together with beta-2-microglobulin. The alpha-1 and alpha-2 domains form a groove whose floor is a beta sheet and whose sides are alpha helices. The groove is largely closed at its ends, so most bound peptides are about 8–11 amino acids long, although longer peptides can sometimes be accommodated by bulging or adopting other conformations. The alpha-3 region contributes to interaction with the CD8 coreceptor on cytotoxic T cells.\n\nClass II molecules consist of an alpha chain and a beta chain, each contributing to the binding platform. Their groove is formed by the alpha-1 and beta-1 domains and is open at both ends. Bound peptides are commonly about 13–25 amino acids long, with a central binding core of approximately nine residues and variable flanking sequences. The lower domains participate in binding the CD4 coreceptor. These structural differences help explain the broad division between class I presentation to CD8 T cells and class II presentation to CD4 T cells.\n\nPeptide binding is selective but not restricted to one unique sequence. Pockets within the groove favor particular side-chain properties at certain peptide positions. For example, some HLA-B27 molecules preferentially bind peptides with arginine at the second position. Such preferences are described as binding motifs. A peptide’s anchor residues contribute strongly to HLA binding, while other residues may face outward and contact the T-cell receptor. Consequently, a change can affect binding stability, T-cell recognition, or both.\n\nThe unit recognized by a T-cell receptor is normally the combined peptide–HLA surface, not free peptide alone. Structural and biochemical studies show that binding strength, complex stability, peptide abundance, and receptor geometry all influence recognition. Nevertheless, peptide–HLA binding does not by itself establish that a peptide will induce an immune response: it must also be produced, transported, displayed, and encountered by an appropriate T cell under suitable activation conditions. This distinction is important when interpreting computational predictions of candidate immune targets."
    },
    {
      "heading": "Antigen processing and presentation pathways",
      "text": "HLA presentation depends on cellular pathways that generate peptides, move them into appropriate compartments, and load them onto HLA molecules. The broad distinction is between class I sampling of intracellular proteins and class II sampling of proteins entering endosomal compartments. These are dominant routes rather than absolute rules: specialized cells can redirect extracellular material into class I presentation, and intracellular material can reach class II compartments.\n\nFor class I presentation, many peptides originate from proteins degraded by the proteasome. These include ordinary cellular proteins, defective products of protein synthesis, viral proteins, and altered proteins produced by tumor cells. Inflammatory signals can change proteasome composition, producing an immunoproteasome with different cleavage preferences. Many resulting peptides are transported into the endoplasmic reticulum by TAP, a transporter composed of TAP1 and TAP2. Endoplasmic-reticulum aminopeptidases, especially ERAP1 and ERAP2, can trim peptide precursors to lengths suitable for binding.\n\nNewly synthesized class I heavy chains associate with beta-2-microglobulin and a peptide-loading complex that includes tapasin, calreticulin, and ERp57. This machinery promotes assembly and the selection of sufficiently stable peptide–HLA complexes. Loaded molecules pass through the Golgi apparatus to the cell surface. Surface complexes are eventually internalized and degraded or recycled. Some class I ligands arise through TAP-independent or otherwise specialized routes, so defects in one processing component do not necessarily eliminate every form of class I presentation.\n\nClass II molecules follow a different pathway. In the endoplasmic reticulum, newly formed alpha and beta chains associate with the invariant chain, CD74, which blocks premature peptide binding and directs the complex toward endosomal compartments. Proteolysis removes most of the invariant chain, leaving a fragment called CLIP in the binding groove. HLA-DM then facilitates CLIP release and peptide exchange, favoring the accumulation of stable complexes. HLA-DO modulates HLA-DM activity in particular cell types and cellular conditions. Many loaded peptides come from proteins internalized by endocytosis or phagocytosis and broken down in acidic endosomal and lysosomal compartments.\n\nAn important exception to the simple intracellular–extracellular division is cross-presentation, in which extracellular antigens are presented by class I molecules. Certain dendritic cells use this process to activate CD8 T cells against viruses or tumors that do not directly infect those antigen-presenting cells. Conversely, autophagy and related delivery routes can bring intracellular proteins into class II compartments. The displayed peptide repertoire is therefore a regulated sample of cellular activity, influenced by protein abundance, degradation, transport, HLA binding preferences, and the activation state of the presenting cell."
    },
    {
      "heading": "Cellular expression, immune recognition, and tolerance",
      "text": "Class I HLA molecules are expressed on nearly all nucleated cells, allowing cytotoxic T cells to survey most tissues. Mature red blood cells are a major exception. Expression levels vary among tissues and can increase in response to interferons, especially during infection or inflammation. Class II expression is concentrated on professional antigen-presenting cells, including dendritic cells, B cells, and macrophages, as well as specialized thymic cells. Interferon-gamma can induce class II expression in additional cell types through regulatory pathways involving the class II transactivator CIITA.\n\nDuring T-cell development in the thymus, HLA molecules help establish both useful recognition and restraint. Positive selection favors developing T cells capable of interacting with self peptide–HLA complexes. Strong recognition of particular self complexes can instead lead to deletion or contribute to specialized developmental outcomes, including some regulatory T-cell populations. Together with mechanisms operating outside the thymus, these processes support immune tolerance. They are not perfectly exhaustive: potentially self-reactive cells can remain in the mature repertoire, making peripheral regulation important.\n\nHLA expression alone is not ordinarily sufficient to activate a previously unprimed T cell. Antigen recognition is integrated with costimulatory signals, inhibitory receptors, and cytokines. This explains why the same peptide–HLA complex can have different consequences depending on the cell presenting it and the surrounding inflammatory context. HLA restriction also means that T cells selected in one individual are adapted to that individual’s inherited set of HLA molecules.\n\nHLA additionally regulates natural killer cells, which do not recognize peptide–HLA complexes through conventional T-cell receptors. Inhibitory killer-cell immunoglobulin-like receptors recognize subsets of HLA-C, HLA-B, and some HLA-A molecules. Another inhibitory receptor, CD94–NKG2A, recognizes HLA-E. These interactions contribute to NK-cell education and the detection of cells with reduced self-HLA expression, often described as “missing-self” recognition. Activation still depends on the balance of multiple inhibitory and activating signals, rather than on HLA loss alone.\n\nNonclassical class I molecules have more specialized roles and generally less sequence diversity than HLA-A, HLA-B, and HLA-C. HLA-E commonly presents leader-sequence peptides derived from other HLA molecules, linking its surface display to the class I assembly pathway. HLA-G has restricted expression, including at the maternal–fetal interface, and interacts with inhibitory immune receptors. HLA-F exhibits context-dependent conformations and receptor interactions. These molecules illustrate how the HLA family extends beyond conventional peptide presentation to CD8 T cells."
    },
    {
      "heading": "Polymorphism, population variation, and evolution",
      "text": "HLA diversity is exceptional both in the number of known alleles and in the frequency with which different variants coexist in human populations. The official IPD-IMGT/HLA database contains tens of thousands of named alleles, with totals increasing as sequencing expands. An allele count is not the same as a count of distinct functional antigen-presenting proteins: some alleles differ only in noncoding sequence, some encode identical protein sequences, and some are not expressed normally. Functional diversity must therefore be evaluated at several levels.\n\nTwo features are particularly important. The system is polygenic, because several different HLA loci encode antigen-presenting molecules, and polymorphic, because individual loci have many alleles. An individual can consequently display multiple class I and class II molecules with different peptide preferences. Heterozygosity at a locus can broaden the combined peptide repertoire relative to having two identical copies, although the degree of functional expansion depends on how different the two molecules are. Two sequence-distinct alleles may still bind substantially overlapping peptide sets.\n\nNatural selection has contributed to the maintenance of this diversity. Evidence for balancing selection includes unusually high variation at peptide-binding positions and patterns of allele persistence across evolutionary lineages. Proposed mechanisms include heterozygote advantage, changing pathogen pressures, and negative frequency-dependent selection, in which pathogens adapted to common host variants leave rarer variants temporarily advantageous. The relative contribution of these mechanisms varies across loci, populations, and historical circumstances; HLA diversity cannot be reduced to one universal evolutionary explanation.\n\nPopulation history also matters. Genetic drift, founder effects, migration, and admixture influence allele and haplotype frequencies. Some HLA variants are common in particular populations and uncommon elsewhere, and extended haplotypes can differ substantially between groups. These patterns are useful in population genetics but do not divide humanity into discrete biological categories. Broad labels such as continental ancestry conceal extensive variation within populations, while individual HLA genotypes cannot be reliably inferred from appearance or a general ancestry designation.\n\nThe combination of selection and demographic history has direct research consequences. A disease association observed in one population may be weaker or absent in another because the relevant allele frequency, linked variants, environmental exposures, or comparison group differs. Likewise, a donor registry can contain many individuals yet still provide uneven coverage of less frequently represented haplotypes. Accurate interpretation therefore requires population-appropriate data, attention to linkage disequilibrium, and a distinction between statistical association and demonstrated molecular mechanism."
    },
    {
      "heading": "Nomenclature, typing, and laboratory interpretation",
      "text": "HLA nomenclature distinguishes broad serological antigens from precisely defined gene alleles. A designation such as HLA-A2 refers to an antigen specificity historically detected by antibodies, whereas HLA-A*02:01 identifies an allele at a defined level of sequence resolution. The modern colon-separated naming convention was introduced in 2010. An allele name begins with the gene, followed by an asterisk and numeric fields separated by colons.\n\nThe first field identifies an allele group, often related to a serological antigen. The second distinguishes alleles encoding different protein sequences. A third field distinguishes synonymous coding-sequence differences, and a fourth distinguishes differences outside the coding sequence. Thus, HLA-A*02:01:01:01 contains information at four levels. Suffixes can indicate expression characteristics: for example, N denotes a null allele and L denotes low cell-surface expression. Other suffixes cover additional expression patterns or uncertainty. Reporting fewer fields generally means that the result has lower resolution, not necessarily that the omitted fields are identical.\n\nHistorically, HLA typing relied heavily on complement-dependent cytotoxicity. In this assay, antibodies binding to a cell’s HLA molecules enable complement-mediated damage, revealing a reaction pattern. Cellular assays also helped characterize class II differences. Molecular methods subsequently transformed typing by examining DNA directly. These include sequence-specific primer assays, sequence-specific oligonucleotide hybridization, and sequence-based typing. The polymerase chain reaction is central to many such methods, while high-throughput and long-read DNA sequencing increasingly permit broader coverage and improved resolution.\n\nHLA typing presents special computational problems because related loci share similar sequences and each locus can have many closely related alleles. Short reads may align to more than one locus or fail to establish which variants occur together on the same chromosome. This latter problem is called phase ambiguity. Incomplete sequencing can also leave uncertainty between an expressed allele and a null allele that differs outside the tested region. “G groups” and “P groups” provide standardized ways of grouping alleles that share specified nucleotide or protein sequences in their antigen-recognition domains.\n\nGenetic typing and antibody testing answer different questions. Typing identifies which HLA variants a person carries; antibody assays investigate immune reactivity against HLA targets. Single-antigen bead assays can help define antibody specificities, and crossmatching assesses donor–recipient compatibility using donor cells or, in a virtual crossmatch, interpreted antibody and typing data. Assay signals require context because antigen density, protein conformation, interference, and laboratory thresholds affect results. A numerical signal from one platform is not a direct, universally standardized measure of antibody concentration or clinical injury."
    },
    {
      "heading": "Transplantation and alloimmune responses",
      "text": "HLA differences are major determinants of transplantation compatibility because the immune system can recognize another person’s HLA molecules as foreign. T-cell recognition of nonself HLA is unusually frequent compared with recognition of any single conventional antigen. This reflects the cross-reactive nature of T-cell receptors and their selection for interactions with peptide–HLA surfaces. Even an HLA molecule with a small number of sequence differences may create a substantially altered recognition surface.\n\nAllorecognition occurs through several routes. In direct allorecognition, recipient T cells recognize intact donor HLA–peptide complexes on donor-derived cells. In indirect allorecognition, recipient antigen-presenting cells process donor proteins, including donor HLA molecules, and display their peptides on recipient HLA. A further route, often termed semidirect recognition, involves recipient cells acquiring intact donor HLA complexes. These mechanisms overlap over time and can contribute differently to acute and persistent graft injury.\n\nAntibodies provide another route of damage. Exposure through pregnancy, transfusion, or a previous transplant can generate anti-HLA antibodies. Donor-specific antibodies may bind graft cells, particularly vascular endothelium, and promote complement activation or recruit immune effector cells. Antibody-mediated rejection is not established by antibody detection alone: assessment also considers graft function, tissue findings, and other evidence. HLA matching reduces particular immune disparities but does not remove every cause of rejection, since minor histocompatibility antigens, non-HLA targets, and nonimmune injury also matter.\n\nIn solid-organ transplantation, the importance and practical weighting of HLA matching vary by organ, urgency, donor availability, and other clinical factors. Kidney transplantation has an extensive history of HLA-based allocation and compatibility assessment. HLA-DR and HLA-DQ differences are particularly relevant to many investigations of antibody formation and long-term outcomes. More detailed approaches evaluate mismatched amino acids, peptide presentation, or antibody-accessible structural configurations sometimes termed eplets. Such measures capture information beyond a simple antigen mismatch count, but different algorithms are not interchangeable.\n\nIn hematopoietic stem-cell transplantation, the donor immune system can attack recipient tissues, causing graft-versus-host disease, while recipient immunity can contribute to graft rejection. High-resolution matching commonly includes HLA-A, HLA-B, HLA-C, and HLA-DRB1, with additional loci considered according to the transplant setting. HLA-DPB1 differences can be classified using models of permissiveness, and haploidentical transplantation deliberately uses a donor sharing one parental haplotype under specialized treatment protocols. Compatibility remains only one component of outcome alongside disease status, donor characteristics, graft source, conditioning, and immune suppression."
    },
    {
      "heading": "Autoimmune disease and drug hypersensitivity",
      "text": "HLA associations are among the strongest reproducible genetic findings in several immune-mediated diseases. Their interpretation requires a distinction between susceptibility and inevitability. A risk-associated allele changes the probability of disease within a particular context; it is usually neither necessary nor sufficient by itself. Because HLA alleles are often inherited in correlated blocks, identifying an association does not automatically identify the responsible molecule, amino acid, or biological pathway.\n\nCeliac disease provides a well-characterized example of peptide presentation contributing to disease. Most affected individuals carry HLA-DQ2.5 or HLA-DQ8, although other related DQ molecules account for some cases. Tissue transglutaminase modifies particular gluten peptides by deamidation, changing selected glutamine residues to glutamate. These negatively charged residues can improve binding to disease-associated DQ molecules, enabling activation of gluten-reactive CD4 T cells. The relevant HLA molecules are much more common than celiac disease itself, demonstrating the importance of additional genetic and environmental factors.\n\nHLA-B27 has a strong association with ankylosing spondylitis and related forms of axial spondyloarthritis, but most carriers do not develop the disease. Proposed mechanisms include presentation of particular peptides, unusual heavy-chain conformations, and effects involving protein folding or innate immune pathways. Their relative contributions remain under investigation. In rheumatoid arthritis, a group of HLA-DRB1 variants encoding the “shared epitope” is associated particularly with disease characterized by antibodies to citrullinated proteins. Type 1 diabetes likewise has strong associations with particular HLA-DR–DQ haplotypes, with some combinations conferring susceptibility and others protection.\n\nDrug hypersensitivity illustrates a different form of HLA-dependent recognition. HLA-B57:01 is strongly associated with hypersensitivity to abacavir. Structural and functional studies show that abacavir can bind within the HLA-B57:01 peptide-binding groove and alter the repertoire of presented self peptides. HLA-B15:02 is associated with carbamazepine-related Stevens–Johnson syndrome and toxic epidermal necrolysis, especially in populations where that allele is relatively frequent. HLA-B58:01 is associated with severe cutaneous adverse reactions to allopurinol. The relationship is drug- and phenotype-specific rather than a general property of all medications.\n\nDifferent mechanisms can produce HLA-associated drug responses, including altered peptide repertoires, covalent drug–protein modification, and direct pharmacological interactions with immune receptors. Clinical interpretation therefore depends on the exact allele, exposure, population, and reaction phenotype. HLA testing is incorporated into established prescribing frameworks for selected drug–allele combinations, but a positive genotype does not by itself demonstrate that an existing symptom was caused by a drug. Conversely, absence of a particular risk allele does not exclude every adverse reaction to that medication."
    },
    {
      "heading": "Infection, cancer, and specialized tissue interfaces",
      "text": "HLA variation affects infection principally by changing which pathogen-derived peptides can be displayed and which T-cell responses can develop. In human immunodeficiency virus infection, certain HLA-B57 and HLA-B27 alleles are associated with improved average viral control in untreated cohorts. These associations involve responses to particular viral regions and constraints on the mutations by which the virus escapes recognition. They are not absolute: viral sequence, other host genes, immune history, and treatment substantially influence individual outcomes.\n\nPathogens can interfere with HLA pathways at several stages. Some viral proteins inhibit TAP-dependent peptide transport, retain class I molecules inside the cell, or accelerate their degradation. Reduced class I presentation can help infected cells evade CD8 T cells, but may increase susceptibility to NK-cell recognition. Viruses can partly counter this trade-off by preserving selected HLA signals or producing molecules that engage inhibitory receptors. Host–pathogen interactions therefore involve a balance between adaptive recognition and innate surveillance, rather than a single escape mechanism.\n\nIn cancer, HLA molecules can present peptides derived from altered proteins, including mutation-generated neoantigens. Tumor-reactive T cells recognize some of these peptide–HLA complexes, providing a basis for several forms of immunotherapy. Tumors can nevertheless escape by losing an HLA allele, disrupting beta-2-microglobulin, altering antigen-processing genes, or changing inflammatory signaling. Loss of one HLA haplotype can remove presentation of selected tumor antigens while preserving other class I molecules. The consequences depend on which antigens were being recognized and which alternative immune pathways remain active.\n\nThese mechanisms shape the development of peptide vaccines, T-cell-receptor therapies, and peptide–HLA-targeting antibodies or bispecific molecules. Such approaches are often restricted to a particular HLA allele because the therapeutic receptor recognizes a defined peptide–HLA combination. Computational models help identify candidates, while mass spectrometry of HLA-bound peptides can provide direct evidence of presentation. Neither predicted binding nor peptide detection alone establishes therapeutic effectiveness or safety; target abundance, tissue distribution, receptor cross-reactivity, and tumor heterogeneity remain separate questions.\n\nThe maternal–fetal interface demonstrates a different specialization. Extravillous trophoblast cells, which invade maternal uterine tissue, characteristically express HLA-C and nonclassical HLA-E and HLA-G, but not the usual classical HLA-A and HLA-B pattern. Their interactions with maternal uterine NK cells and other immune cells participate in the regulation of placentation and tissue remodeling. This is not simple immune invisibility: maternal cells can detect fetal-associated signals, while local receptor interactions, cellular differentiation, and regulatory networks shape the response. Studies of maternal KIR and fetal HLA-C combinations illustrate how HLA can influence interactions between two genetically distinct individuals without transplantation or infection."
    }
  ],
  "links": [
    "major-histocompatibility-complex",
    "immune-system",
    "leukocyte",
    "t-cell",
    "antibody",
    "x-ray-crystallography",
    "chromosome",
    "complement-system",
    "allele",
    "chromosomal-crossover",
    "amino-acid",
    "t-cell-receptor",
    "proteasome",
    "endoplasmic-reticulum",
    "cell-membrane",
    "phagocytosis",
    "dendritic-cell",
    "erythrocyte",
    "interferon",
    "antigen-presenting-cell",
    "b-cell",
    "macrophage",
    "clonal-deletion",
    "regulatory-t-cell",
    "immune-tolerance",
    "t-cell-costimulation",
    "cytokine",
    "natural-killer-cell",
    "natural-selection",
    "genetic-drift",
    "population-genetics",
    "dna",
    "polymerase-chain-reaction",
    "dna-sequencing",
    "graft-versus-host-disease",
    "cancer",
    "mass-spectrometry"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}